<DOC>
	<DOC>NCT01565928</DOC>
	<brief_summary>The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.</brief_summary>
	<brief_title>Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Willing and able to provide informed consent; Men, 18 years of age or older; Histologically or cytologically confirmed adenocarcinoma of the prostate; Ongoing androgen deprivation therapy Severe concurrent disease; Known or suspected brain metastasis; History of another malignancy within the previous 5 years; Prior treatment with docetaxelbased chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>MDV3100</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
</DOC>